Clinical trials: Huntington's Dementia
Huntington Disease
The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease
The goal of this clinical trial is to learn if oral supplement of nicotinamide riboside (NR), a form of vitamin B3, slows disease progression in adults with Huntington's disease.
- Trial name
- NAD-HD (NCT06853743)
- Testing
- Nicotinamide Riboside (NR)
- Where
- Norway
- Volunteers
- 120 people
- Sponsor
- Oslo University Hospital
Huntington Disease
Clinicopathological MRI and CSF Correlates in Huntington's Disease.
In this study the investigators will link brain iron levels obtained from quantitative susceptibility maps of HD patients with specific and well-known clinical CSF markers for iron accumulation, neurodegeneration and…
- Trial name
- NCT05534139
- Testing
- 7T MRI-scan, CSF collection via lumbar puncture, Blood withdrawal
- Where
- Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Huntington Disease
Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study
This trial examines whether 12 weeks of time-restricted eating (TRE), otherwise known as intermittent fasting, appears safe and feasible in persons with early-stage Huntington's disease (HD).
- Trial name
- TREHD (NCT06490367)
- Testing
- Time-Restricted Eating Diet
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Oregon Health and Science University
Huntington Disease, Irritability
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
The purpose of this study is to assess efficacy and safety of dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) in patients with irritability due to Huntington's disease.
- Trial name
- NCT03854019
- Testing
- Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Huntington Disease
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia.
- Trial name
- OPEN-HART (NCT01306929)
- Testing
- pridopidine
- Volunteers
- 134 people
- Sponsor
- Prilenia
Huntington Disease, Deep Brain Stimulation
Deep Brain Stimulation Treatment for Chorea in Huntington's Disease
1. Evaluating therapeutic effects of globus pallidus internus (GPi) deep brain stimulation (DBS) on Huntington's disease (HD) patients with chorea； 2.
- Trial name
- NCT04244513
- Testing
- Deep brain stimulation
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Huntington's Disease
Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD
This study will examine the ways in which people reveal their status as a carrier of Huntington s disease (HD) or of being at risk for the disease.
- Trial name
- NCT00491842
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Huntington Disease
Cognitive Assessment Tools for Huntington's Disease.
The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and…
- Trial name
- CAT-HD (NCT06546488)
- Testing
- Assessments
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Ohio State University
Huntington Disease
The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease
This is an open label, dose escalation clinic trial of ER2001 intravenous injection to evaluate safety, tolerability and pharmacokinetics of ascending single and multiple doses of intravenously administered ER2001 in patients…
- Trial name
- NCT06024265
- Testing
- ER2001 injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- ExoRNA Bioscience
Huntington's Disease, Chorea
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
- Trial name
- NCT07601516
- Testing
- Deutetrabenazine
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Huntington's Disease
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
- Trial name
- NCT06585449
- Testing
- ALN-HTT02
- Where
- 19 sites in Canada, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Alnylam Pharmaceuticals
Huntington Disease
Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease
Huntington disease (HD, 1.3/10 000) is an autosomal dominant disease due to an abnormal expansion of CAG triplets in HTT gene. Several pathophysiological mechanisms have been evoked, including an alteration of the signaling…
- Trial name
- LCR-MH (NCT04012411)
- Testing
- Brain MRI, Lumbar Punction, Blood sample
- Where
- France
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Huntington Disease
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
- Trial name
- HART (NCT00724048)
- Testing
- ACR16
- Where
- 28 sites in United States, Canada
- Volunteers
- 227 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Huntington Disease
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients
This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety and efficacy of daily MBF-015 oral treatment during 28 days in Huntington's Disease patients on top of standard of care.
- Trial name
- NCT06469853
- Testing
- MBF-015 16 mg oral capsules
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Medibiofarma S.L.
Huntington's Disease
Efficacy and Safety of Tetrabenazine in Chorea
The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo
- Trial name
- NCT00219804
- Sponsor
- Prestwick Pharmaceuticals
Huntington Disease
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
- Trial name
- NCT05358717
- Testing
- PTC518
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.
- Trial name
- INVEST-HD (NCT07326709)
- Testing
- Votoplam (blinded)
- Where
- 117 sites in United States, Argentina and 25 more
- Volunteers
- 770 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
A Pre-Cellular Therapy Observational Study in Early Huntington's Disease
This observational study will establish a clinical baseline and measure changes over time in movement, thinking, behavior, brain imaging, blood and spinal fluid markers in subjects with early stage Huntington's disease.
- Trial name
- PRE-CELL (NCT01937923)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of California, Davis
Huntington's Disease
Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease (HD).
- Trial name
- NCT02074410
- Testing
- OMS643762
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Omeros Corporation
Movement Disorders, Essential Tremor
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
The proposed study is to evaluate the effectiveness of ExAblate Transcranial MRgFUS as a tool for creating a unilateral lesion in the Vim thalamus or the globus pallidus (GPi) in patients with treatment-refractory symptoms of…
- Conditions
- Movement Disorders, Essential Tremor, Holmes Tremor, Parkinson's Disease
- Trial name
- NCT02252380
- Testing
- Transcranial ExAblate System
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- InSightec